Regeneron’s Inmazeb drug receives FDA approval for treating Ebola virus
Category: #headlines  By Nikita Chaurasia  Date: 2020-10-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Regeneron’s Inmazeb drug receives FDA approval for treating Ebola virus

According to reliable sources, New York-headquartered biotechnology company, Regeneron Pharmaceuticals Inc. has recently made it to the headlines after its patented Inmazeb drug received approval from the U.S. FDA (Food & Drug Administration) for the treatment of the Ebola virus.

For the record, Inmazeb is a mixture of three monoclonal antibodies, namely maftivimab, atoltivimab, and odesivimab-ebgn. The drug stops the spread of Ebola virus by inhibiting glycoprotein present on the surface of this virus. The antibodies present in it can bind to this glycoprotein and block attachment and virus invasion into healthy cells.

Reportedly, Inmazeb was initially evaluated in a clinical trial round called the PALM trial, that included over 382 individuals infected with the Ebola virus. The trial round was conducted amidst the Ebola virus outbreak between 2018 and 2019 and was led by the Institut National de Recherche Biomédicale along with the U.S. National Institutes of Health.

It is to be noted that the initial symptoms observed after the dosage of Inmazeb included vomiting, tachypnea, tachycardia, chills, and fever. In this context, Regeneron was reported stating that the treatment can give rise to infusion-related events such as hypersensitivity and subsequently discontinued the trial.

However, a recent study by Regeneron revealed that the treatment of patients with Ebola virus using Inmazeb revealed a primary efficacy end point of over 28-day mortality. Additionally, 51% of the 154 patients involved in the study showed rapid recovery.

Regeneron Pharmaceuticals Inc. is reportedly working on the development of REGN-COV2, a drug aimed at the treatment of the COVID-19 virus.

In other news, American multinational pharmaceutical company, Pfizer Inc. has reportedly received provisional determination from the Australian regulatory body, TGA (Therapeutic Goods Administration) for its COVID-19 vaccine, mRNA (messenger ribonucleic acid).

Source credits:

Reference link: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
By Nikita Chaurasia

According to reliable sources, Massachusetts-headquartered clinical stage biopharmaceutical company, Syndax Pharmaceuticals Inc. has revealed an updated data from its Phase 1 trial of its patent axatilimab. The company will reportedly present the dat...

Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
By Nikita Chaurasia

Shares of Xiaomi Corporation, a Chinese multinational electronics company, witnessed a 7.1% drop during Hong Kong trading after the company secured USD 3.91 billion in fund raising which also included the city’s top-up placement. The company h...

Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
By Nikita Chaurasia

Israel-based leading provider of advanced solutions for cybersecurity, IoT (Internet of Things) and e-Government sectors Supercom has reportedly signed a supply agreement to deliver its PureSecurity EM (Electronic Monitoring) product suite in Wiscons...